Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta, Prometheus Close Deal for miRNA Dx Market Rights

Premium

Rosetta Genomics this week announced that its previously announced license and collaboration deal with Prometheus Laboratories has closed.

The deal, unveiled earlier this month, gives Prometheus the US market rights to Rosetta's three microRNA-based diagnostics, including miRview Meso, which differentiates lung cancer from mesothelioma; miRview Mets, which is designed to determine the source of cancers of unknown primary origin; and miRview Squamous, which is designed to differentiate squamous from non-squamous non-small cell lung cancer (see RNAi News, 4/16/2009).

As part of the deal, Rosetta and Prometheus will also jointly develop two additional miRNA-based gastroenterology diagnostics.

The companies also said that Prometheus' planned purchase of 2 million shares of Rosetta at $4 per share has been completed.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.